At Epitracker, our mission is to discover novel therapeutics that expand longevity and improve life for both humans and animals. Epitracker is advancing discovery and development of a suite of novel therapeutics aimed to improve global health in the areas of cardiometabolic disease, neurodegenerative disease, and other diseases of aging. Epitracker has demonstrated broad cardiometabolic benefits, mechanism of action, high bioavailablity, and safety of its lead oral therapeutic, ETI-101. Series A financing will be used to advance ETI-101 through FDA IND approval. Epitracker has exclusive licensing rights from the U.S. Navy to five issued U.S. patents and nine pending U.S. and international patents.